



**AZB & PARTNERS**  
ADVOCATES & SOLICITORS

# PHARMACEUTICALS

AZB & Partners is the preferred counsel in the pharmaceutical sector. Our clients include Indian and international pharmaceutical companies, as well as leading private equity investors.

Our work includes:

- Advising investors on a range of transactional matters, including M&As and fund raising
- Advising on structuring of pharmaceutical deals from an Indian regulatory standpoint
- Advising on business reorganizations and commercial contracting
- Advising on IP licensing and technical collaborations
- Auditing IP portfolios

Additionally, in conjunction with our market-leading corporate, regulatory, tax and competition practices, we regularly advise operators, as well as investors on a range of regulatory matters, including on ethical practices relating to interactions with medical practitioners, compliance with advertising and marketing codes, licensing requirements, pricing issues and clinical trials.

[www.azbpartners.com](http://www.azbpartners.com)





Glaxo SmithKline on its minority share acquisition in GlaxoSmithKline Consumer Healthcare for US\$ 690 million, pursuant to a voluntary offer made under the SEBI takeover regulations.



Pfizer on (i) the sale of its Capsugel business to KKR; and (ii) the global restructuring of its animal health business, including the divestment of its Indian animal health business.



Actavis Pharma Group in relation to (i) its acquisition of the active pharmaceutical ingredient manufacturing division of Sanmar Specialty Chemicals; and (ii) the sale of its API facility Nuray Chemicals.



The Dabur Group on (i) its acquisition of a stake in several companies, such as the Balsara Group and Fem Care Pharma; (ii) IFC's PE investment in Dabur Pharma; and (iii) the sale of its non-oncology formulations business to Alembic.

### THE CARLYLE GROUP

Carlyle on its (i) US\$ 210 million majority stake acquisition in Sequent Scientific, the largest pure-play animal healthcare company in India, followed by a mandatory open offer under the SEBI takeover regulations (currently ongoing); and (ii) 20% acquisition in Piramal Pharma for US\$ 481 million.



Famcare ('FCL'), its shareholders and Jai Pharma ('JPL') on the (i) demerger of its female contraceptive business into JPL; and (ii) US\$ 800 million sale of JPL by FPL's existing shareholders to Mylan Laboratories.



The Kemwell Group, including its promoters, on the sale of its pharma contract development and manufacturing business in India, US and Sweden, to Recipharm AB.



Claris Lifesciences on the transfer of its infusion business for India and emerging markets to its joint venture company with Otsuka Pharmaceutical Factory and Mitsui for US\$ 170 million.



Natera on (i) license agreements for its gene sequencing technology; and (ii) laws relating to Good Clinical Practice Guidelines, clinical trials, interactions with investigators, biomedical research and export / shipment of biological samples outside India.



Ascent Health and Wellness Solutions on Evermed Holdings' subscription of approximately 55% of its share capital for US\$ 60 million.



Novartis India with respect to the (i) implications of a common law license; and (ii) laws and regulations governing the online sale of drugs in India and interactions with medical practitioners.



Advent on its majority stake acquisition in Bharat Serums and Vaccines, a leading biopharmaceutical company with presence in India and emerging markets.



Leapfrog Investments on its acquisition of a controlling stake in Ascent Meditech, a leading Indian manufacturer of medical devices and healthcare products.



Bristol Myers Squibb with respect to (i) developing and securing its IP rights; and (ii) its agreements relating to a research partnership with Syngene, a wholly owned subsidiary of Biocon.



Merck Sharp & Dohme on (i) licensing and supplying its pharmaceutical products and vaccines; (ii) managing its IP; and (iii) complying with regulatory requirements in India.



Torrent Pharmaceuticals with respect to successfully enforcing its brand 'Chymoral Forte' against Wockhardt.